Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma
- PMID: 28352186
- PMCID: PMC5359136
- DOI: 10.2147/OTT.S132187
Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma
Abstract
Background: Epidermal growth factor receptor (EGFR) is a commonly altered gene that is identified in various cancers, including head and neck squamous cell carcinoma (HNSCC). Therefore, EGFR is a promising molecular marker targeted by monoclonal antibodies and small molecule inhibitors targeting the tyrosine kinase (TK) domain.
Objective: The objective of this study was to investigate the spectrum of mutations in exons 18, 19, 20, and 21 of the EGFR gene in HNSCC patients.
Materials and methods: This retrospective study included 47 confirmed HNSCC cases. Mutations in the TK domain, exons 18, 19, 20, and 21 of the EGFR gene, were detected by Scorpion® chemistry and ARMS® technologies on Rotor-Gene Q real-time polymerase chain reaction.
Results: The tumors exhibited EGFR-TK domain mutations in 57% of cases. Four cases of T790M mutations were reported for the first time among HNSCC patients. Out of the total mutations, L861Q (exon 21), exon 20 insertions and deletions of exon 19 accounted for the majority of mutations (21%, 19%, and 17%, respectively). EGFR mutation status was correlated with the higher grade (P=0.026) and advanced stage (P=0.034) of HNSCC tumors.
Conclusion: Higher frequency of EGFR-TK domain mutations together with the presence of the T790M mutation suggests that identification of these mutations might streamline the therapy and provide a better prognosis in HNSCC cases.
Keywords: T790M; deletions; insertions; real-time PCR; somatic mutations; therapy.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures

Similar articles
-
Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC).Biomarkers. 2014 May;19(3):198-206. doi: 10.3109/1354750X.2014.895852. Epub 2014 Apr 8. Biomarkers. 2014. PMID: 24712396
-
Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Pathol Res Pract. 2011. PMID: 21531084 Review.
-
[Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancers by real-time polymerase chain reaction using scorpion amplification refractory mutation system].Zhonghua Bing Li Xue Za Zhi. 2008 May;37(5):294-9. Zhonghua Bing Li Xue Za Zhi. 2008. PMID: 18956645 Chinese.
-
Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas.Oral Oncol. 2011 Jun;47(6):487-96. doi: 10.1016/j.oraloncology.2011.03.020. Epub 2011 Apr 16. Oral Oncol. 2011. PMID: 21498106
-
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8. J Oncol Pharm Pract. 2016. PMID: 25855240 Review.
Cited by
-
Identification of Potential Biomarkers and Survival Analysis for Head and Neck Squamous Cell Carcinoma Using Bioinformatics Strategy: A Study Based on TCGA and GEO Datasets.Biomed Res Int. 2019 Aug 7;2019:7376034. doi: 10.1155/2019/7376034. eCollection 2019. Biomed Res Int. 2019. PMID: 31485443 Free PMC article.
-
Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer.Oncol Lett. 2019 Sep;18(3):2427-2433. doi: 10.3892/ol.2019.10565. Epub 2019 Jul 4. Oncol Lett. 2019. PMID: 31404155 Free PMC article.
-
Curcumin: A Potential Weapon in the Prevention and Treatment of Head and Neck Cancer.ACS Pharmacol Transl Sci. 2024 Oct 14;7(11):3394-3418. doi: 10.1021/acsptsci.4c00518. eCollection 2024 Nov 8. ACS Pharmacol Transl Sci. 2024. PMID: 39539276 Review.
-
Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma.Front Med (Lausanne). 2023 Feb 2;10:1066021. doi: 10.3389/fmed.2023.1066021. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36817764 Free PMC article. Review.
-
Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis.Cell Oncol (Dordr). 2025 Feb;48(1):123-138. doi: 10.1007/s13402-024-00962-6. Epub 2024 Jun 18. Cell Oncol (Dordr). 2025. PMID: 38888847 Free PMC article.
References
-
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. - PubMed
-
- Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22. - PubMed
-
- Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials. 2013;34(34):8690–8707. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous